THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR TO BE TRANSMITTED, DISTRIBUTED TO, OR SENT BY, ANY NATIONAL OR RESIDENT OR CITIZEN OF ANY SUCH COUNTRIES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION MAY CONTRAVENE LOCAL SECURITIES LAWS OR REGULATIONS. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF REGULATION (EU) NO. 596/2014 ON MARKET ABUSE, AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AND REGULATION (EU) NO. 596/2014 ON MARKET ABUSE. CASCAIS, Portugal, June 15, 2026 (GLOBE NEWSWIRE) — Pulsar Helium Inc. (AIM: PLSR)...

Hilde Garssen, KPN’s Chief People Officer and member of the Board of Management, will leave KPN on 1 September to join ING as Chief HR Officer and member of the Management Board Banking. Hilde joined KPN in December 2018 as Chief People Officer and has served on KPN’s Board of Management since 1 December 2019. Gerard van de Aast, Chair of the Supervisory Board: “Hilde has played a key role in KPN’s transformation. She has helped to build a strong culture, modernized our employment proposition and strengthened engagement and leadership across the company. Hilde has also helped strengthen KPN’s appeal as an employer. We are grateful for her contribution to KPN and wish her every success in her new role at ING.” Hilde Garssen: “Over the past 7.5 years, I have had the privilege of shaping KPN’s people strategy in support of KPN’s broader strategy...

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL This announcement does not constitute an offering circular, or a prospectus as defined by Regulation (EU) No. 2017/1129 of 14 June 2017, as amended (the “Prospectus Regulation”) and nothing herein shall be construed as an offering of securities. Completion of InstallatørGruppen A/S’ Initial Public Offering With reference to company announcement no. 1-2026 dated 3 June 2026 related to the publication of the initial public offering (the “Offering”) and admission to trading of all of the shares of InstallatørGruppen A/S (“InstallatørGruppen” or the “Company”) to trading on Nasdaq Copenhagen A/S (“Nasdaq...

ING appoints Hilde Garssen to the Management Board Banking ING announced today that Hilde Garssen will be appointed to the Management Board Banking (MBB) as chief human resources officer (CHRO), effective 1 September 2026. Hilde is currently chief people officer and a member of the Board of Management at KPN. She will succeed Ruth McGill, who left ING in November 2025. Isaac Vitini has overseen the CHRO role on an ad interim basis since then. The addition of the CHRO to the MBB reflects the increasing importance of our people and culture in our strategy aimed at becoming the best European bank by accelerating growth, increasing impact, and delivering value. This is especially relevant in light of the significant transformation of ING, ongoing technological developments and growing customer expectations. Hilde Garssen has more than 25...

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL This announcement does not constitute an offering circular, or a prospectus as defined by Regulation (EU) No. 2017/1129 of 14 June 2017, as amended (the “Prospectus Regulation”) and nothing herein shall be construed as an offering of securities. No termination or withdrawal of InstallatørGruppen A/S’ initial public offering With reference to company announcements no. 1-2026 dated 3 June 2026 regarding the publication of the offering circular in connection with the initial public offering (the “Offering”) and admission of the shares of InstallatørGruppen A/S (“InstallatørGruppen” or the “Company”) to...

Worldline announces the completion of its reverse share split Adjustment of the conversion/exchange ratio of the OCEANEs, the exercise parity of the Options, and the allocation rights of the Performance Shares and Free Shares Paris, La Défense, 15 June 2026 – Worldline S.A. [ISIN: FR0011981968 – Euronext: WLN] (the “Company” or “Worldline”), a European leader in payment services, announces today the completion of the reverse share split of the shares comprising its share capital, decided by Worldline’s Board of Directors at its meeting held on 28 April 2026 in accordance with the tenth resolution approved by Worldline’s shareholders at the general meeting held on 8 January 2026 (the “Shareholders’ Meeting”), through the exchange of forty (40) existing shares with a par value of two euro cents (€0.02) each (the “Existing Shares”) for one...

BW Opal achieves Interim Performance Test milestone BW Offshore is pleased to announce the successful completion of the Interim Performance Test (IPT) for the BW Opal FPSO, as part of the commissioning programme for the Santos-operated Barossa LNG project offshore northern Australia. The completion of IPT constitutes an important operational milestone for BW Opal. The test confirms that key production, processing and utility systems on the FPSO are operating in an integrated manner and are capable of delivering stable performance under production conditions. Following the restart of production in early May, BW Opal has continued gas production and export. Production is being managed in close coordination with Santos during this phase of the ramp-up and commissioning programme. BW Offshore remains focused on safe and stable operations, the completion...

Sampo plc, stock exchange release, 15 June 2026 at 8:30 am EEST Sampo plc’s share buybacks week 24/2026 During week 24 (8 June 2026 – 12 June 2026), Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:Market (MIC Code) Daily volume (in number of shares) and weighted average price of the purchased shares, EUR* Aggregated weekly volume (in number of shares) and weighted weekly average price of the purchased shares, EUR*    08/06/2026 09/06/2026 10/06/2026 11/06/2026 12/06/2026 Week 24/2026, totalAQEU Volume 5,189 792 1,476 1,920 4,457 13,834Average price 8.88 8.97 8.94 9.02 9.07 8.97CEUX Volume 150,799 46,126 93,364 17,928 109,480 417,697Average price 8.88 8.94 8.97 9.04 9.06 8.96TQEX Volume 43,251 14,496 24,784 8,659 35,239 126,429Average...

RUEIL-MALMAISON, France and TAIPEI, Taiwan, June 15, 2026 (GLOBE NEWSWIRE) — Schneider Electric, a global energy technology leader, today announced a strategic collaboration with Hon Hai Technology Group (Foxconn), the world’s largest electronics manufacturer, to help define and scale the next generation of AI data centers. As AI adoption surges, the demands on digital infrastructure are being fundamentally reshaped. This collaboration brings together Foxconn’s unmatched expertise in advanced compute platforms, AI rack integration, and global manufacturing with Schneider Electric’s leadership in power systems, cooling, and energy management. Together, the companies aim to deliver integrated, ready-to-deploy solutions that enable customers to build and operate AI infrastructure with greater speed, efficiency, and predictability...

BEIJING, June 15, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that over 40 clinical studies of the Company’s novel BTK inhibitor orelabrutinib were presented at the European Hematology Association (EHA) 2026 Congress. Clinical data on the efficacy and safety of orelabrutinib in treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients from the United States and Europe was released for the first time. A series of clinical studies on orelabrutinib covered multiple hematological malignancies, including CLL/SLL, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and primary central nervous system lymphoma (PCNSL)....